Pathway | MSEA | Meta-MSEA | ||||
---|---|---|---|---|---|---|
Human | Mouse | Mouse | Mouse | |||
GWAS | GWAS | TWAS | EWAS | Value | FDR | |
Glycolysis/Gluconeogenesis | 2.56 | 0.88 | 3.84 | 0.63 | 4.73 | 2.22Â % |
Starch and sucrose metabolism | 3.67 | 1.37 | 3.29 | 0.17 | 4.57 | 2.22Â % |
Regulation And Function Of ChREBP in Liver | 3.10 | 0.93 | 2.74 | 0.41 | 4.08 | 3.60Â % |
Nuclear Receptors in Lipid Metabolism and Toxicity | 5.58 | 0.48 | 1.99 | 0.35 | 4.00 | 3.60Â % |
Regulation of gene expression in beta cells | 4.16 | 1.75 | 1.48 | 0.19 | 3.97 | 3.60Â % |
Type II diabetes mellitus | 2.11 | 1.09 | 1.48 | 1.08 | 3.66 | 6.00Â % |
Integration of energy metabolism | 2.42 | 0.33 | 2.17 | 1.09 | 3.34 | 10.82Â % |
Steroid biosynthesis | 1.10 | 2.04 | 1.27 | 0.76 | 3.10 | 14.34Â % |
alpha-linolenic acid (ALA) metabolism | 3.40 | 0.32 | 1.72 | 0.69 | 3.09 | 14.34Â % |
Incretin Synthesis, Secretion and Inactivation | 3.24 | 1.14 | 0.09 | 2.06 | 3.02 | 14.34Â % |
Adipocytokine signaling pathway | 2.55 | 0.41 | 1.13 | 1.26 | 2.94 | 14.34Â % |
Chylomicron-mediated lipid transport | 0.43 | 0.89 | 2.89 | 1.26 | 2.92 | 14.34Â % |
Glucose transport | 5.57 | 1.31 | 0.27 | 0.29 | 2.92 | 14.34Â % |